1-[3-(1-triphenylmethylimidazol-4-yl)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]thiourea | 199522-60-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-[3-(1-triphenylmethylimidazol-4-yl)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]thiourea
• 英文别名: 1-[3-[(4-bromophenyl)methyl-pyridin-2-ylamino]propyl]-3-[3-(1-tritylimidazol-4-yl)propyl]thiourea
• CAS: 199522-60-6
• 化学式: C₄₁H₄₁BrN₆S
• 分子量: 729.787
• InChiKey: SKBAMDYJFONCBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  49
• 可旋转键数：
  15
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  90.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[3-(1-triphenylmethylimidazol-4-yl)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]thiourea 在 盐酸 、 sodium hydride 作用下， 以 乙醇 为溶剂， 反应 75.0h， 生成 3-[3-(imidazol-4(5)-yl)propyl]-1-{3-[N-(4-bromobenzyl)-N-(pyrid-2-yl)amino]propyl}-S-methylisothiourea hydroiodide dihydrochloride
  参考文献：
  名称：

  Discovery of a Novel Non-Peptide Somatostatin Agonist with SST₄ Selectivity

  摘要：

  The discovery of novel non-peptide compounds with a high affinity for the peptide hormone somatostatin (SST) receptor is described. The compounds were tested for affinity at five human SST receptor subtypes individually expressed in mammalian cells. The compound NNC 26-9100 showed a K-i of 6 nM at SST4 and more than 100 fold selectivity for SST4 over SST1, SST2, SST3, or SST5. Competition binding studies and Scatchard analysis of the interaction by NNC 26-9100 with SST showed specificity at SST4. Furthermore, NNC 26-9100 was highly selective for SST4 over a variety of other G protein-coupled receptors, having affinities for M-1 muscarinic acetylcholin and D-3 dopamine receptors of around 500 and 1000 nM, respectively. Finally, NNC 26-9100 was found to fully inhibit forskolin-induced accumulation of adenosine 3',5'-cyclic monophosphate in baby hamster kidney cells, expressing the human SST4 receptor with an EC50 of 2 nM.

  DOI：

  10.1021/ja973325x
• 作为产物：
  描述：

  甲基3-(1H-咪唑-4-基)丙酸酯盐酸盐 在 lithium aluminium tetrahydride 、 一水合肼 、 三乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 4.0h， 生成 1-[3-(1-triphenylmethylimidazol-4-yl)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]thiourea
  参考文献：
  名称：

  Discovery of a Novel Non-Peptide Somatostatin Agonist with SST₄ Selectivity

  摘要：

  The discovery of novel non-peptide compounds with a high affinity for the peptide hormone somatostatin (SST) receptor is described. The compounds were tested for affinity at five human SST receptor subtypes individually expressed in mammalian cells. The compound NNC 26-9100 showed a K-i of 6 nM at SST4 and more than 100 fold selectivity for SST4 over SST1, SST2, SST3, or SST5. Competition binding studies and Scatchard analysis of the interaction by NNC 26-9100 with SST showed specificity at SST4. Furthermore, NNC 26-9100 was highly selective for SST4 over a variety of other G protein-coupled receptors, having affinities for M-1 muscarinic acetylcholin and D-3 dopamine receptors of around 500 and 1000 nM, respectively. Finally, NNC 26-9100 was found to fully inhibit forskolin-induced accumulation of adenosine 3',5'-cyclic monophosphate in baby hamster kidney cells, expressing the human SST4 receptor with an EC50 of 2 nM.

  DOI：

  10.1021/ja973325x

文献信息

• Somatostatin agonists and antagonists
  申请人：Novo Nordisk A/S

  公开号：US06127343A1

  公开（公告）日：2000-10-03

  The present invention relates to compounds, compositions containing them, and their use for treating medical disorders related to binding to human somatostatin receptor subtypes.

  本发明涉及化合物、包含它们的组合物以及它们用于治疗与人类生长抑素受体亚型结合相关的医学疾病的用途。
• Use of somatostatin agonists and antagonists for treating diseases
  申请人：Novo Nordisk A/S

  公开号：US06159941A1

  公开（公告）日：2000-12-12

  The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib ##STR1## or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

  本发明涉及使用非肽源的生长抑素受体配体，例如一般式Ia或Ib ##STR1##或其药学上可接受的盐，该配体具有对生长抑素受体蛋白SSTR4的高和/或选择性亲和力，并用于制备治疗哺乳动物视网膜和/或虹膜睫状体不良病变相关疾病的药物。这些疾病包括高眼压（IOP）和/或深部眼部感染。可以治疗的疾病包括青光眼、角膜炎、虹膜炎、视网膜炎、白内障和结膜炎等。
• USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE
  申请人：NOVO NORDISK A/S

  公开号：EP1019050B1

  公开（公告）日：2002-03-20
• SOMATOSTATIN AGONISTS AND ANTAGONISTS
  申请人：NOVO NORDISK A/S

  公开号：EP0912551A1

  公开（公告）日：1999-05-06
• US6127343A
  申请人：——

  公开号：US6127343A

  公开（公告）日：2000-10-03